Eli Lilly Reports Breakthrough Phase 3 Jaypirca Results
Indianapolis, Indiana | April 13, 2026 Eli Lilly and Company has announced positive topline results from the Phase 3...
Eli Lilly
Advertisement
Lilly Launches Foundayo Oral GLP-1 Weight Loss Drug
INDIANAPOLIS, April 9, 2026 Eli Lilly and Company has announced the U.S. launch of Foundayo™ (orforglipron), a first-in-class oral...
FDA Approves Lilly Foundayo Oral GLP-1 Weight Loss Drug
INDIANAPOLIS, USA — April 1, 2026 In a landmark advancement in obesity treatment and metabolic disease management, Eli Lilly...
Lilly to Acquire Centessa in $7.8B Pharma Deal
INDIANAPOLIS, USA & BOSTON, USA & LONDON, UK, March 31, 2026 Eli Lilly and Company has announced a definitive...
Insilico, Lilly Sign $2.75B AI Drug Discovery Deal
Hong Kong | March 30, 2026 Strategic AI Collaboration to Accelerate Drug Discovery Insilico Medicine has announced a major...
Advertisements
Lilly Taltz Zepbound Combo Shows Strong Phase 3b Results
Indianapolis, USA | March 28, 2026 Phase 3b Study Demonstrates Superior Clinical Outcomes Eli Lilly and Company has announced...
FDA Breakthrough Status for Lilly’s Sofetabart Mipitecan ADC
Indianapolis, January 20, 2026 — Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has...
Lilly and NVIDIA Invest $1B in AI-Driven Drug Discovery
SAN FRANCISCO, January 12, 2026 — NVIDIA and Eli Lilly and Company announced the creation of a first-of-its-kind AI...
Lilly to Acquire Ventyx to Expand Oral Inflammation Therapies
INDIANAPOLIS | January 7, 2026 — Eli Lilly and Company has announced an agreement to acquire Ventyx Biosciences, a...
Lilly’s Oral GLP-1 Orforglipron Sustains Weight Loss in Phase 3 Trial
Indianapolis, December 18, 2025 — Eli Lilly and Company announced positive topline results from its first-of-its-kind Phase 3 ATTAIN-MAINTAIN...
Advertisement
